TP Therapeutics
Clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD6.3b (Public information from Jun 2022)
Share price
$76.01 TPTX
San Diego California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$1.4m | Early VC | ||
N/A | N/A | Series B | |
$18.0m | Late VC | ||
$45.0m | Series C | ||
$80.0m | Series D | ||
N/A | N/A | IPO | |
* | N/A | $203m | Post IPO Equity |
* | N/A | $374m | Post IPO Equity |
* | N/A | $460m | Post IPO Equity |
* | $4.1b Valuation: $4.1b | Acquisition | |
Total Funding | AUD223m |
Related Content
Recent News about TP Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.